"OVATION has strategically concentrated its research efforts on developing treatments for the often overlooked rare and orphan disease market, avoiding many of the pitfalls other company's face when strictly pursuing blockbuster therapies and indications," says Frost & Sullivan Research Analyst Misty Hughes.
"Through selective partnerships and financial responsibility, OVATION
, having justly labeled itself the 'Partner of Choice,' has built a solid organization with uniquely strong capabilities required for specialized therapies for rare diseases."
Fueled by the desire to provide life-sustaining therapies for severely ill, vastly underserved patient populations, OVATION
has applied its commercial, regulatory and manufacturing expertise to develop partnerships with top companies - Merck
, Abbott Laboratories
, among others - resulting in sustaining much-needed treatment options on the market, as well as building an enviable late-stage development pipeline.
With a core focus on disorders of the central nervous system (CNS), hematology and oncology, neonatal intensive care (NIC), and hospital-based therapies, this company of nearly 300 industry professionals boasts a portfolio of 20 pharmaceutical products with sales in more than 85 countries worldwide, and a reported five year compound annual growth rate of 85 percent.
"Many of OVATION's
compounds acquired through partner company divestitures or out-license agreements are currently available and being successfully marketed, both locally and globally, or are in the late-stages of clinical trials for approval in the U.S.," says Hughes